Miyakawa Kei, Kato Hideaki, Ohtake Norihisa, Jeremiah Sundararaj Stanleyraj, Ryo Akihide
Department of Microbiology, Yokohama City University School of Medicine, Kanagawa, Japan.
Infection Prevention and Control Department, Yokohama City University Hospital, Kanagawa, Japan.
J Infect Dis. 2023 Jan 11;227(2):221-225. doi: 10.1093/infdis/jiac344.
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised concerns regarding vaccine effectiveness. We investigated humoral and cellular immune responses against SARS-CoV-2 in healthcare workers before and after a third (booster) dose of the BNT162b2 messenger RNA vaccine. It significantly enhanced both humoral and cellular immunity in previously uninfected individuals. However, cellular immunity was not enhanced in previously infected persons, suggesting that 3 antigenic stimuli by vaccination or natural infection reached a plateau of cellular immunity. Even with reinforced immunity to SARS-CoV-2, we confirmed several postbooster breakthrough cases caused by the Omicron variant.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的奥密克戎变异株引发了人们对疫苗有效性的担忧。我们调查了医护人员在接种第三剂（加强）BNT162b2信使核糖核酸疫苗前后针对SARS-CoV-2的体液免疫和细胞免疫反应。它显著增强了先前未感染个体的体液免疫和细胞免疫。然而，先前感染过的个体的细胞免疫并未增强，这表明通过疫苗接种或自然感染的3次抗原刺激使细胞免疫达到了平台期。即使对SARS-CoV-2的免疫力得到增强，我们仍确认了几例由奥密克戎变异株引起的加强针接种后突破感染病例。
